Original language | English |
---|---|
Number of pages | 2 |
Journal | Annals of Oncology |
Volume | 29 |
DOIs | |
Publication status | Published - Dec 2018 |
Externally published | Yes |
Event | ESMO Immuno-Oncology Congress 2018 - Geneva, Switzerland Duration: 13 Dec 2018 → 16 Dec 2018 |
A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors
S. Deva, J-S. Lee, C-C. Lin, C-J. Yen, M. Millward, Y. Chao, B. Keam, M. Jameson, M-M. Hou, Y-K. Kang, B. Markman, C-H. Lu, K-M. Rau, K-H. Lee, L. Horvath, M. Friedlander, A. Hill, J. Wu, J. Hou, J. Desai
Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review
11
Citations
(Web of Science)